Thyroid disorders are common in pregnancy and affect maternal and fetal outcome.
Introduction
During pregnancy, the demand of iodine is significantly higher than that in nonpregnant women [1 ,2 ,3] . Whereas the daily requirement of iodine in nonpregnant women is at least 100 mg/day, this increases to about 200-250 mg/day to maintain free thyroxine (fT4) during pregnancy within the normal range. This higher requirement of iodine is necessary because of an increase by around 50% of maternal thyroxine production, a transfer of iodine to the fetus and an increased renal iodine clearance [1 ,4] . The median urinary iodine concentration is recommended by the WHO/ICCIDD/UNICEF for assessment of iodine intake in nonpregnant and pregnant women. Taking into account the higher requirement in pregnancy, the urinary iodine concentration should be between 150 and 249 mg/l [1 ].
Not only iodine deficiency is a major concern for the mother and the fetus during pregnancy, but autoimmune thyroid disease (AITD) also is a main problem, as it not only affects fertility [5] but also may lead to a decreased thyroid reserve and a decrease in available thyroxine, especially in the first half of pregnancy, in which the development of the fetus depends on the delivery of thyroxine from the mother [4, 6 ] . Graves' disease is rare in pregnant women but transfer of stimulating receptor antibodies (TSAbs) to the child may induce thyrotoxicosis of the child [7 ] . This review addresses the effect of iodine deficiency and AITD in pregnant women on morbidity and outcome of the offspring. The importance of thyroid function testing in early pregnancy is emphasized.
Iodine deficiency
Deficient iodine intake in pregnancy mostly occurs in developing countries but may also occur in many countries in Europe where 52% of the population is affected by insufficient iodine intake, but in the United States only around 11% are affected by deficient iodine intake [1 ] . However, recent data revealed that the mean urinary iodine concentration in United States declined from 327 mg/l determined in the National Health and Nutrition Examination Survey I (NHANES I) to 141 mg/l (NHANES III) in women of reproductive age [8] . Recent data from the NHANES 2003-2004 confirmed the stabilization of urinary iodine levels; the median urinary iodine concentration was 139 mg/l in this age group [9 ] . These data, however, indicate that the iodine intake of pregnant and nonpregnant women in the United States is slightly below that recommended by WHO/ICCIDD/UNICEF for urinary iodine concentration in pregnant women. It has to be considered that when the median urinary iodine is around 140 mg/l, then around 50% of pregnant women are below the recommended range.
Growth of the thyroid gland and even the development of thyroid nodules might be the consequence for the mother [2 ,10]. In Europe, nearly in all countries except Finland and the Netherlands, where iodine intake is sufficient, the thyroid volume increases from 15 to 31% during pregnancy [1 ], indicating a mild-to-moderate iodine deficiency. In two recent studies, thyroid growth during pregnancy despite sufficient iodine intake was reported. One reason might be a family history of thyroid diseases [11 ] . In the other trial [12 ], the iodine excretion was borderline low during the third trimester and thyroidstimulating hormone (TSH) increased, indicating borderline low iodine and an increase in iodine loss through the kidney because of elevated cardiac output. They did not consider the pregnancy-adjusted higher iodine demand during pregnancy [2 ].
Using iodized salt consumption at least 2 years before pregnancy in a mild iodine-deficient area (Northern Sicily) significantly reduced maternal thyroid failure, but shortterm use only during pregnancy did not [13 ] . The prevalence of maternal thyroid failure was six-fold higher in the short-term compared with long-term use of iodized salt. In the same area, another study was performed to evaluate the occurrence of hypothyroidism during pregnancy in mildly iodine-deficient pregnant women. From 426 women screened, 108 were already taking thyroid hormones and 98 were not eligible or could not be followed [14 ] . The remaining 220 women were never tested for thyroid dysfunction before pregnancy. TSH, fT4 and thyroid-specific antibodies (TAbs) were tested in early pregnancy and twice per trimester. The women with hypothyroidism were treated with levothyroxine. The overall prevalence of hypothyroidism was 11%, from these 57.7% already were hypothyroid in the first trimester. Positive TAbs were detected in 8.2%. The relative risk for hypothyroidism in TAb-positive mothers was five-fold higher compared with TAb-negative mothers. Hypothyroxinemia developed in 25.4% of pregnancies, mostly from the second trimester onwards. Although the incidence of hypothyroidism in TAb-positive pregnant women was five-fold higher, in 70% of hypothyroid women, the cause was iodine deficiency. This study has two implications: first, thyroid function should be tested not only at the beginning of pregnancy but also be monitored at least once in every trimester in mild iodine-deficient areas and second, iodine supplementation during pregnancy is strongly recommended [14 ] .
Thyroid hormones and brain development Iodine deficiency during pregnancy has long been known as a cause for maternal and consequently fetal hypothyroxinemia that adversely affects cognitive development of children [2 ,15] . In a meta-analysis of studies conducted in China, the IQs of children (<16 years) living in naturally iodine-sufficient areas were compared with those in severely iodine-deficient areas, or children in iodine-deficient areas born before or after the introduction of iodine supplementation [16] . The IQs of children living in chronic iodine deficiency were 12 points lower compared with those living in iodine-sufficient areas. Children of those women receiving iodine during pregnancy had a 4.8 points lower IQ. Whether mild or moderate maternal iodine deficiency is associated with more subtle neuropsychological effects is a matter of debate [17 ] . No controlled long-term intervention studies have been performed so far in humans [1 ].
Thyroxine and not TSH seems to be most important for normal brain development, as shown in many experimental animal trials [4] . This could be confirmed in a recent study using genome array analysis (Affymetrix Rat 230A) to compare the gene expression in the neocortex and hippocampus in neonate pups of rats treated with different amounts of propylthiouracil. These data clearly show that there is a continuum in the disturbance of genes important for neuronal development [18 ] . Low thyroxine, but normal TSH in dams and pups already significantly affected gene expression (46% in hippocampus and 12% in cortex).
In humans, it has been shown that elevated TSH during pregnancy is associated with an increased risk of mental and cognitive disturbance in the children [19] . However, it has been shown that children of women with hypothyroxinemia and still normal TSH during gestation had a delayed mental and motor function at 1 and 2 years of age [20] . Therefore, not only TSH but also fT4 should be monitored, especially in the first half of pregnancy.
Reference values of normal thyroid function during pregnancy
The reference values for TSH and fT4 for nonpregnant women may not be alienable to pregnant women. To evaluate normal TSH and fT4 during first and second trimester, these parameters were determined in 9562 women in the FaSTER (first and second-trimester evaluation of risk for aneuploidy) trial [21 ] . Positive TAbs were detected in 1211 (12.7%) women. The median TSH was 1.00 mU/l in the first trimester and 1.19 mU/l in the second trimester in TAb-negative mothers. Women with positive TAb had higher TSH in the first (1.64 mU/l) and the second trimester (1.73 mU/l). Median fT4 was 1.10 ng/dl in first trimester and 1.01 ng/dl in second trimester and was lower in women with TAb (1.05 ng/ dl in first trimester and 0.98 ng/dl in second trimester; Table 1 ). Women with known hypothyroidism had been excluded and therefore these data can be used as reference, although there are some limitations. The tests were done after delivery and whether some women were treated during the pregnancy is unknown.
Recently, the reference values of TSH in the first trimester (9-11 weeks of pregnancy) have been evaluated in 5520 women from the central part of the Czech Republic, an area with former iodine deficiency [22 ] . The reference interval (2.5-97.5th percentile) was 0.06-3.67 mU/l in nonselected women. A suppressed TSH was found in 2.9% and elevated TSH in 4.48%. Positive TAb was found in 11.2% women. These data confirm the results from the FaSTER trial. In addition, they confirmed the high prevalence of undetected subclinical hypothyroidism and positive TAb in unselected pregnant women.
Requirement and monitoring of levothyroxine substitution in pregnancy with known hypothyroidism
In an observational study [23 ] , it was examined whether pregnant women with known hypothyroidism were sufficiently supplemented with levothyroxine to keep TSH and fT4 within the reference ranges. The mean TSH levels were significantly higher compared with the reference values in the women with positive TAb in first (2.29 vs. 1.11 mU/l) and second trimester (2.07 vs. 1.34 mU/l).
The proportion of women with hyperthyroidism (TSH<0.01 mU/l) was not significantly different from that of those without known thyroid dysfunction. The TSH values of 43% of hypothyroid women were above the reference value for the first trimesterand33%forthe second trimester. The fT4 levels were not significantly different from the reference values of women with elevated TAb. These data clearly show that management of pregnant women with known hypothyroidism has to be improved. It is, however, until now unknown whether the offspring of the women with slightly elevated TSH and normal fT4 will be affected, as thyroxine is more important for brain development than TSH, as outlined above [4, 17 ] .
In a recent retrospective study on pregnant women under levothyroxine supplementation [24 ], only 51% had TSH values within the reference range, whereas 19% had suppressed TSH values and 30% TSH values more than 4.0 mU/l. Fetal loss was significantly higher (29 vs. 6%) in the women with abnormal TSH values. Although this study has some limitations, it clearly demonstrates the importance of a close monitoring of women with known hypothyroidism under treatment already in early pregnancy and adaption of the levothyroxine medication.
The requirement of levothyroxine in pregnant women depends on the etiology of the hypothyroidism as recently shown [25 ] . Patients were divided into three groups: patients with primary hypothyroidism, patients with hypothyroidism after treatment because of Graves' disease or goiter and patients after thyroidectomy because of thyroid cancer. Pregnant women with primary hypothyroidism required an increase in levothyroxine dosage of 11% in the first and 16% in the second and third trimesters. Those with treated Graves' disease or goiter required 27% more levothyroxine in the first, 51 and 45% in the second and third trimesters, whereas the cancer patients required only an increase in levothyroxine of 9% in the first and 21 and 26% in the second and third trimesters.
Thyroid diseases in pregnancy Gä rtner 503 TAb, thyroid-specific antibody; TSH, thyroid-stimulating hormone. Adapted from [21 ] .
Patients with known hypothyroidism should be tested already before conception and on confirmation of pregnancy. The aim is to keep TSH less than 2.5 mU/l in the first and less than 3 mU/l in the later pregnancy. Thyroid function should be monitored 4-6 weekly and L-thyroxine dosage should be adapted. Thyroid function has to be rechecked at 6 weeks after delivery [26 ] .
Although not all pregnant women need an increase in levothyroxine substitution, especially when they are well treated before conception [27 ] , close monitoring of these women is recommended. It should be considered that the absorption of levothyroxine is decreased in patients with autoimmune gastritis, which is often associated with AITD, Helicobacter pylori infection and several other medications [28, 29] .
The role of autoimmune thyroiditis
The role of thyroid autoimmunity has been extensively reviewed in the last years [5,6 ,30,31]. Not only women with overt hypothyroidism due to AITD but also those with positive TAb, but still euthyroidism have a higher (2.3-fold) risk for early abortion [32, 33] . The results from all studies evaluating the risk of preterm delivery in TAbpositive pregnancies have recently been reviewed [34 ] . The risk for preterm delivery is two-three-fold higher in TAb-positive women and the birth weight is significantly lower at least in some trials.
In a large prospective population-based trial from northern Finland including 9247 singleton pregnancies, only 5805 could be followed. The aim of the study was to evaluate perinatal mortality, preterm delivery, absolute and gestational birth weight as well as absolute and relative placental weight [35 ] . Antithyroid peroxidase (anti-TPO) positive were 4.96% and TgAb (thyroglobulin Ab) positive 4.90%. Preterm birth occurred only in subclinical hypothyroid women, 50% of them were TAb-positive. Perinatal death was associated with maternal TAb positivity at the end of the first trimester but not maternal thyroid hormone status (1.3% when TPO Ab was positive and 2.2% when TgAb was positive). TPO Ab-positive mothers had more often large-for gestational-age infants (2.4 vs. 0.8%) and also mothers with subclinical hyperthyroidism (6.6 vs. 2.5%).
The advantages of the study are the large cohort and the whole thyroid function testing; the disadvantage was that only once the thyroid function test was done at the end of the first trimester. Early abortion was not examined in this study as only intact pregnancies were followed.
The neonatal outcome and maternal characteristics of pregnant women with primary hypothyroidism have been described in a recent publication [36 ] . All medical reports of pregnant women from 1995 to 2004 (n ¼ 861 989) were retrospectively examined. The neonatal outcomes of the women taking levothyroxine already at early (n ¼ 8907) pregnancy or later (n ¼ 905) were identified. Data of the mothers without thyroid disease were also analyzed, which were adjusted for confounders and compared with those taking levothyroxine. Women with known diabetes before pregnancy were excluded. Women taking levothyroxine had an increased rate of preeclampsia [odds ratio (OR) 1.32, confidence interval (CI) 1.19-1.47], caesarean sections or induction of labor. The risk for preterm delivery was marginally increased (OR 1.13, CI 1.03-1.25). Neonatal thyrotoxicosis was detected in seven and one unspecified; the expected number is 0.2. Early abortion could not be determined as only intact pregnancies were examined, but women taking levothyroxine had a more frequent history of previous miscarriages (OR 1.12, CI 1.07-1.18).
The limitation of this study is that no information was available on the thyroid hormone status of the mothers, but it is assumed that the majority of women were suffering from AITD, as Sweden is an area with sufficient iodine intake.
The reason for the higher rate of early abortion and at least in some studies, preterm delivery in TAb-positive mothers is uncertain, but a decrease in thyroid reserve had been postulated or a direct role of the autoimmune disease [6 ,33] . To date, there is only one successful placebo-controlled interventional trial, in which pregnant women with positive TAb but normal TSH (n ¼ 115) were treated with levothyroxine or placebo [37] . The women were substituted with levothyroxine: 0.5 mg/kg per body weight when TSH was less than 1.0 mU/l, 0.75 mg/kg when TSH was between 1.0 and 2.0 mU/l and 1 mg/kg when TSH was more than 2.0 mU/l or placebo. The early abortion rate was reduced from 13 to 2% and the preterm delivery from 22.4 to 7%. These results emphasize the hypothesis that the thyroid reserve during pregnancy in women with TAb is insufficient.
In an autoimmune thyroiditis animal model, mice were immunized with recombinant mouse thyroid peroxidase (rmTPO). The animals developed anti-TPO Abs and were allowed to mate [38 ] . The most important finding of this study was that preimplantation embryos showed anti-TPO Abs bound to the membrane of the blastomere of 8-cell to morula-stage embryos. These data may indicate that anti-TPO Abs are directly involved in early abortion and higher infertility rates in AITD.
Hyperthyroidism in pregnancy
The management of hyperthyroidism in pregnancy, which most often is caused by Graves' disease, has been reviewed recently [7 ,26 ,39 ] . Hyperthyroidism occurs in about 0.2-0.4% of all pregnancies. Hyperthyroidism should be distinguished from gestational transient thyrotoxicosis, which is due to the TSH-receptor stimulating effects of human choriogonadotropin (hCG) [40, 41] . This hCG-induced hyperthyroidism is mostly mild and need not be treated. Only rare cases with extremely high hCG (i.e. due to a hydatidiform mole) might induce severe thyrotoxicosis [42 ] .
The signs and symptoms of hyperthyroidism due to Graves' disease may aggravate in the first trimester and thereafter may become mild. Untreated hyperthyroidism is associated with severe effects on maternal and neonatal outcome. The risk for premature fetal loss, preeclampsia, preterm delivery, intrauterine growth retardation and low birth weight is significantly increased [41] . It has to be considered that the TSAbs are transferred from the mother to the child, and therefore the fetus is at risk to develop Graves' disease. Close monitoring of the fetus is, therefore, strictly recommended, even in mothers treated by thyroidectomy before pregnancy but have still elevated TSAbs [7 ] .
Propylthiouracil is the drug of choice, as for methimazole (MMI) a higher incidence of choanal atresia and aplasia cutis is proposed [43, 44 ] . There, however, still remains the question whether indeed MMI or more likely the hyperthyroidism might be responsible for this malformation. A recent multicenter case-control study revealed that of 61 mothers, 10 (16.4%) mothers were treated with MMI compared with two of 183 controls (1.1%) [44 ] . The authors' conclusion is that hyperthyroidism is more likely to be responsible for the choanal atresia. This is because in one mother, MMI treatment was started at 7 months of pregnancy, four were treated with levothyroxine together with MMI and hyperthyroxinemia is not excluded. Further controlled trials are necessary to resolve this question.
Screening for thyroid dysfunction in pregnancy?
In countries with known iodine deficiency, the incidence of thyroid disorders is significantly higher compared with countries with iodine sufficiency [2 ]. But the prevalence of TAb is between 5 and 18% independent of iodine intake [26 ,45 ] . Thyroid dysfunction as well as only the presence of TAbs has been shown to affect substantially the maternal and fetal outcome as outlined above. Therefore, some experts strongly recommend universal screening either before conception or at least when pregnancy is confirmed [26 ] . The American College of Obstetrics and Gynecology (ACOG) does not recommend routine screening of thyroid function in pregnancy because of lack of studies showing a proven benefit, even if asymptomatic subclinical hypothyroidism is known and treated [46] . In contrast, the American Association of Clinical Endocrinologists recommends routine TSH screening before or during the first trimester [47] . The Endocrine Society only recommends thyroid screening in women at risk for thyroid disorders [48] . These risk factors include a personal and family history of thyroid diseases, signs and symptoms of thyroid dysfunction, autoimmune diseases like type 1 diabetes, history of neck and head irradiation or infertility. But this case-finding might overlook a substantial number of women with subclinical thyroid dysfunction [49] . In two retrospective analyses, both screening for TSH and anti-TPO autoantibodies have been shown to be cost-effective [50 ] , even when no improvement in child IQ outcomes was assumed [51 ] . Therefore, we would strongly agree with those experts and recommend routine screening in early pregnancy. The mothers with positive TAbs or TSH and fT4 values outside the pregnancy-adjusted reference values should be monitored throughout pregnancy [52] . Those with positive TAb should also be followed postpartum, because they are at high risk for developing post-partum thyroiditis [53 ] .
Conclusion
Both iodine deficiency and AITD are frequent in pregnancy and affect maternal and neonatal morbidity. Thyroid dysfunction is more frequent in areas with mild-tomoderate iodine deficiency. Iodine deficiency causes thyroid growth in mothers and more importantly affects the neuropsychological development of the offspring. Mothers with positive TAb and still normal thyroid function exhibit significantly more early abortion and preterm delivery. A supplementation with levothyroxine in early pregnancy reduces the risk of miscarriage and preterm delivery significantly. Pregnant women on levothyroxine replacement therapy are often over or undertreated.
There is an ongoing debate on the effectiveness of routine screening in early pregnancy. Taking into account the high prevalence of thyroid disorders during pregnancy with increased morbidity, screening of all pregnant women for TSH, fT4 and TAb is emphasized as soon as pregnancy is confirmed or even better before pregnancy. This is also recommended in countries with sufficient iodine intake. The pregnancy-adapted reference values should be used for diagnosis and management of maternal thyroid dysfunction.
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